Company profile

Ticker
BMY, BMY-RI, CELG-RI
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
220790350

BMY stock data

(
)

Calendar

6 Aug 20
20 Sep 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
4 Sep 20 Derica W Rice Call Option (obligation to sell) Common Stock, $0.10 par value Sell Dispose S No 72.5 12 870 0
1 Sep 20 Derica W Rice Deferred Share Units Common Stock, $0.10 par value Grant Aquire A No 60.97 1,306.279 79.64K 1,306.279
1 Sep 20 Santiago Karen Murphy Common Stock, $0.10 par value Payment of exercise Dispose F No 60.97 220 13.41K 8,170
1 Sep 20 Santiago Karen Murphy Common Stock, $0.10 par value Option exercise Aquire M No 0 642 0 8,390
1 Sep 20 Santiago Karen Murphy RSU Common Stock, $0.10 par value Option exercise Dispose M No 0 642 0 0
1 Sep 20 Price Paula A Deferred Share Units Common Stock, $0.10 par value Grant Aquire A No 60.97 1,306.279 79.64K 1,306.279
96.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2202 2097 +5.0%
Opened positions 223 143 +55.9%
Closed positions 118 216 -45.4%
Increased positions 1063 795 +33.7%
Reduced positions 686 927 -26.0%
13F shares
Current Prev Q Change
Total value 986.35B 892.55B +10.5%
Total shares 2.17B 1.68B +29.2%
Total puts 24.38M 29.73M -18.0%
Total calls 28.94M 22.92M +26.3%
Total put/call ratio 0.8 1.3 -35.1%
Largest owners
Shares Value Change
Vanguard 203.89M $11.99B +2.5%
BLK BlackRock 165.73M $9.63B -2.8%
STT State Street 99.11M $5.83B -1.7%
JPM JPMorgan Chase & Co. 75.93M $3.84B +25.6%
FMR 71.97M $3.88B +4.3%
Wellington Management 63.65M $3.74B -15.7%
Pentwater Capital Management 53.54M $191.69M NEW
Renaissance Technologies 49.55M $2.58B -24.9%
Laurion Capital Management 48.57M $196.32M +1440.8%
Farallon Capital Management 47.83M $371.39M NEW
Largest transactions
Shares Bought/sold Change
Pentwater Capital Management 53.54M +53.54M NEW
Farallon Capital Management 47.83M +47.83M NEW
Laurion Capital Management 48.57M +45.42M +1440.8%
Abrams Capital Management 23.2M +23.2M NEW
Viking Global Investors 18.97M +18.97M NEW
CS Credit Suisse 24.64M +18.27M +286.7%
JHG Janus Henderson 38.18M +16.51M +76.2%
Renaissance Technologies 49.55M -16.44M -24.9%
JPM JPMorgan Chase & Co. 75.93M +15.5M +25.6%
Citadel Advisors 15.98M +14.66M +1109.7%

Financial report summary

?
Risks
  • The COVID-19 pandemic is affecting our business and could have a material adverse effect on us.
  • It is possible that the COVID-19 pandemic could delay the timing of the FDA’s approval decisions for liso-cel and ide-cel, which could have a material adverse effect on our contingent value rights (CVRs).
  • U.S. executive orders on biopharmaceutical pricing and other potential initiatives by the U.S. federal government to implement measures to regulate drug pricing in the future could adversely affect our business.
Management Discussion
  • (a) Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
  • (b) Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales.
  • •U.S. revenues for the second quarter 2020 and year-to-date were impacted by Revlimid and other Celgene products ($2.9 billion and $5.7 billion, respectively), which contributed 80% of the growth for both periods, and higher demand for Eliquis, partially offset by lower demand for Opdivo. The second quarter was negatively impacted from sales channel inventory work down and lower new patient starts due to COVID-19. Average net selling prices increased 3% in both periods.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: abroad, absence, adherent, antiretroviral, Arabia, argument, ASR, BCMA, begun, bio, biomarker, bluebird, carefully, causation, Chemistry, confidential, Cormorant, diffuse, disallowance, enacted, endoscopic, favorable, feasibility, fewer, GILTI, globe, half, heard, heavily, HPI, insulin, introduce, jointly, Kaposi, KarMMa, lentiviral, lethal, lethality, lt, Lupin, MAA, mandating, mediastinal, metastic, ORR, physician, pioneering, precision, preliminarily, pressure, pressuring, pretreated, preview, provisional, recommenced, recover, recovered, regressing, Repare, restarted, resumption, sarcoma, Saudi, slower, stringent, switch, switching, synthetic, timeframe, True, UC, Union, vector, wider, worldwide
Removed: acceptance, anticancer, burden, China, cohort, conducted, CRC, damage, Dana, defend, demonstrate, description, diagnosed, expecting, Farber, Infusion, intolerant, maintained, meeting, mg, minimum, monotherapy, positive, progressed, randomized, receiving, recent, sBLA, show, stable, structural, syringe, topline, trading, voted, withdrawal